Related Experiment Video

Updated: Jun 24, 2026

DNA Vector-based RNA Interference to Study Gene Function in Cancer
13:10

DNA Vector-based RNA Interference to Study Gene Function in Cancer

Published on: June 4, 2012

Therapeutic potential of RNA interference in drug-resistant cancers

Hermann Lage1

  • 1Charité Campus Mitte, Institute of Pathology, Berlin, Germany. hermann.lage@charite.de

Future Oncology (London, England)
|March 17, 2009
PubMed

Insights

Multidrug resistance in cancer hinders chemotherapy. RNA interference (RNAi) technology offers a promising alternative strategy to overcome this challenge by targeting ATP-binding cassette (ABC)-transporters, potentially leading to new cancer therapeutics.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Multidrug resistance (MDR) is a significant clinical challenge in cancer therapy.
  • Overexpression of ATP-binding cassette (ABC)-transporters frequently mediates MDR.
  • Previous attempts using small molecule inhibitors of ABC-transporters have yielded disappointing clinical results.

Purpose of the Study:

  • To explore RNA interference (RNAi) as an alternative therapeutic strategy to overcome MDR in cancer.
  • To review and discuss the application of various RNAi strategies in preclinical cancer models.
  • To evaluate the potential of RNAi-based therapies for clinical development.

Main Methods:

  • Investigated RNA interference (RNAi) strategies targeting ABC-transporter overexpression.
  • Applied various RNAi approaches in in vitro and in vivo tumor models.
  • Reviewed and analyzed existing study results on RNAi for MDR reversal.

Main Results:

  • RNAi strategies have shown promise in reversing multidrug resistance in various cancer models.
  • Successful application of RNAi in both in vitro and in vivo settings demonstrates its potential.
  • The effectiveness of different RNAi approaches in overcoming MDR is being evaluated.

Conclusions:

  • RNA interference (RNAi) technology presents a viable alternative for overcoming cancer multidrug resistance.
  • Further research and development are needed to translate RNAi strategies into effective clinical therapeutics.
  • Targeting ABC-transporters with RNAi holds significant potential for future cancer treatment.

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi07:56

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi

Published on: August 18, 2010

Related Concept Videos

RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...